The year 2023 was a busy one for regulatory, compliance, and enforcement developments in the life sciences industries, and 2024 promises to be even busier.
In the life sciences industry, understanding key regulations and updates stands as a critical cornerstone for ensuring product safety, quality, and efficacy. The industry is subject to a myriad of stringent regulations and standards set by global health authorities, making compliance a complex and multifaceted challenge.
The life sciences industry faces an intricate framework of regulations spanning various aspects such as drug development, manufacturing, distribution, and post-market surveillance.
As someone whose job is to comply with a regulatory framework in the life science industry, you need to adopt a proactive and strategic approach, balancing the risks and responsibilities with the benefits and opportunities.
Navigating through this regulatory framework demands meticulous adherence, documentation, and reporting, imposing substantial complexities and operational burdens on companies in this sector. A regulatory framework is a set of rules, standards, and guidelines that govern the development, approval, and marketing of products and services in a specific industry or sector.
One example of a regulatory framework for life science industry is the Title 21 Code of Federal Regulations (CFR), which is used by the U.S. Food and Drug Administration (FDA), the Office on National Drug Control Policy (ONDCP), and the Drug Enforcement Agency (DEA) to regulate food, drugs, cosmetics, and other public health products2.
The Title 21 CFR consists of 50 chapters and over 1,400 parts, covering various aspects of the life science industry, such as:
- Quality systems: These are the requirements for establishing and maintaining a quality management system that ensures the safety, effectiveness, and compliance of products and processes. For example, Part 820 specifies the quality system regulation for medical devices2.
- Clinical trials: These are the requirements for conducting and reporting clinical studies that evaluate the safety and efficacy of products and services. For example, Part 312 specifies the investigational new drug application for human drug and biological products2.
- Labeling and advertising: These are the requirements for providing accurate and truthful information about the products and services to the consumers and health care professionals. For example, Part 201 specifies the labeling requirements for prescription drugs2.
- Post-market surveillance: These are the requirements for monitoring and reporting the performance, adverse events, and recalls of products and services after they are marketed. For example, Part 803 specifies the medical device reporting for manufacturers, importers, and user facilities2.
The Title 21 CFR is an example of a regulatory framework for life science industry that aims to protect public health and promote innovation and competitiveness in the industry.
However, Title 21 CFR is not the only regulatory framework that applies to the life science industry, as there are also other national and international regulations and guidelines that may affect the industry, such as the European Medicines Agency (EMA), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), and the International Organization for Standardization (ISO)1.
Life science companies need to be aware of and comply with the relevant regulatory frameworks that apply to their products and services.
Complying with a regulatory framework in the life science industry is a complex and challenging task, as it involves meeting the quality, safety, and efficacy standards set by the relevant authorities for the products and services offered by the industry.
Some of the steps that someone can take to comply with a regulatory framework in the life science industry are:
- Understanding the regulatory requirements: The first step is to identify and understand the regulatory requirements that apply to the specific product or service, as well as the market or region where it is intended to be used.
This may involve researching the laws, regulations, and guidelines issued by the regulatory agencies, such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)1.
It may also involve consulting with experts, professionals, or consultants who have experience and knowledge in the relevant field2.
- Establishing and maintaining a quality system: The second step is to establish and maintain a quality system that ensures the safety, effectiveness, and compliance of the products and processes.
This may involve implementing and following the best practices and standards for quality management, such as the Good Manufacturing Practice (GMP), the Good Laboratory Practice (GLP), the Good Clinical Practice (GCP), and the Good Automated Manufacturing Practice (GAMP)3.
It may also involve documenting and recording the quality procedures, policies, and activities, as well as conducting regular audits and inspections to monitor and evaluate the quality performance4.
- Conducting and reporting clinical trials: The third step is to conduct and report clinical trials that evaluate the safety and efficacy of the products and services.
This may involve designing and executing the clinical studies according to the scientific and ethical principles and standards, such as the Declaration of Helsinki and the Nuremberg Code5.
It may also involve submitting and obtaining the approval of the investigational new drug application (IND) or the investigational device exemption (IDE) from the regulatory agencies, as well as reporting the results and adverse events of the clinical trials.
- Labeling and advertising the products and services: The fourth step is to label and advertise the products and services in a way that provides accurate and truthful information to consumers and healthcare professionals.
This may involve complying with the labeling and advertising requirements and regulations issued by regulatory agencies, such as the Prescription Drug Marketing Act (PDMA) or the Federal Trade Commission (FTC).
It may also involve reviewing and updating the labels and advertisements to reflect the latest evidence and data, as well as responding to feedback and complaints from consumers and healthcare professionals.
- Monitoring and reporting the post-market performance: The fifth step is to monitor and report the post-market performance of the products and services after they are marketed.
This may involve collecting and analyzing the data and information on the quality, safety, and efficacy of the products and services, such as adverse events, recalls, or customer satisfaction.
It may also involve submitting and complying with the post-market surveillance and reporting requirements and regulations issued by the regulatory agencies, such as the medical device reporting (MDR) or the periodic safety update report (PSUR).
Your responsibility is to comply with a regulatory framework where you need to adopt a proactive and strategic approach, balancing the risks and responsibilities with the benefits and opportunities.
There are a handful of free and paid regulatory intelligence subscription sites that report on life science regulatory compliance, validation, quality affairs, and GxP-related topics.
Many of these services do a decent job of putting need-to-know industry content in front of you, but few—if any—provide the expert analysis and perspectives that help you understand what you need to do in light of, say, new guidance being issued.
CoursWorx Professional Subscription offers premium content that delivers life science validation and compliance news, as well as highly actionable analysis.
As a subscriber, you can keep up on validation and regulatory compliance emerging trends seen through the lens of those who’ve worked in FDA-regulated industries. Our content fills a gap. We cover the areas that are important to you and distill them into actionable takeaways.
